General Information of Drug (ID: DMTUVCG)

Drug Name
MIK665 Drug Info
Synonyms
1799631-75-6; (2~{R})-2-[5-[3-chloranyl-2-methyl-4-[2-(4-methylpiperazin-1-yl)ethoxy]phenyl]-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl]oxy-3-[2-[[2-(2-methoxyphenyl)pyrimidin-4-yl]methoxy]phenyl]propanoic acid; (R)-2-((5-(3-chloro-2-methyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl)oxy)-3-(2-((2-(2-methoxyphenyl)pyrimidin-4-yl)methoxy)phenyl)propanoic acid; MIK-665; S-64315; SCHEMBL16815710; EX-A2912; NSC809971; NSC-809971; MIK665; S-64315; HY-112218; CS-0044179; (5R)-(R)-2-((5-(3-Chloro-2-methyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl)oxy)-3-(2-((2-(2-methoxyphenyl)pyrimidin-4-yl)methoxy)phenyl)propanoic acid; 1799831-02-9; OK5
Indication
Disease Entry ICD 11 Status REF
Acute myeloid leukaemia 2A60 Phase 1 [1]
Cross-matching ID
PubChem CID
118157243
TTD Drug ID
DMTUVCG

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Patented Agent(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Obatoclax DMPF9ZM Solid tumour/cancer 2A00-2F9Z Phase 2 [3]
AZD5991 DM7QGHO Haematological malignancy 2B33.Y Phase 1 [4]
AMG 176 DM0Q7NO Acute myeloid leukaemia 2A60 Phase 1 [4]
PRT1419 DMIKE0O Melanoma 2C30 Phase 1 [5]
ABBV-467 DM87SM9 Multiple myeloma 2A83 Phase 1 [6]
AMG 397 DM7CNTG Refractory hematologic malignancy 2A85.5 Phase 1 [7]
PMID27744724-Compound-18 DM73S2C N. A. N. A. Patented [8]
Indole-based analog 2 DM0NEVC N. A. N. A. Patented [8]
PMID27744724-Compound-10 DMFKS2P N. A. N. A. Patented [8]
PMID27744724-Compound-21 DM18UA5 N. A. N. A. Patented [8]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1) TTL53M6 MCL1_HUMAN Inhibitor [2]

References

1 ClinicalTrials.gov (NCT02979366) Phase I Study of S64315 Administred Intravenously in Patients With Acute Myeloid Leukaemia or Myelodysplastic Syndrome. U.S. National Institutes of Health.
2 MCL1 inhibitors S63845/MIK665 plus Navitoclax synergistically kill difficult-to-treat melanoma cells. Cell Death Dis. 2020 Jun 8;11(6):443.
3 Phase II study of obatoclax mesylate (GX15-070), a small-molecule BCL-2 family antagonist, for patients with myelofibrosis. Clin Lymphoma Myeloma Leuk. 2010 Aug;10(4):285-9.
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 Clinical pipeline report, company report or official report of Prelude Therapeutics.
6 Clinical pipeline report, company report or official report of AbbVie.
7 Clinical pipeline report, company report or official report of Amgen.
8 Mcl-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Feb;27(2):163-178.